Subscribe
pavel-kapysh-lundbeck
Pavel Kapysh / Shutterstock.com
30 March 2021EuropeAlex Baldwin

Lundbeck loses €150m pay-for-delay appeal

Lundbeck has lost an appeal to the  Court of Justice of the European Union (CJEU) to waive €150 million ($176 million) in fines levied against itself and a group of five generics manufacturers over ‘pay-for-delay’ deals for its antidepressant generics.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

More on this story

Generics
Why the ‘first penguin’ of pay for delay has not come in Japan: anatomy of a Japan paradox
27 May 2022   Why does Japan have no reverse payments culture? Takanori Abe of Abe & Partners unpicks a complex issue.
Big Pharma
EU General Court backs Lundbeck fine in pay-for-delay case
12 September 2016   The EU General Court has backed the European Commission’s decision to fine pharma company Lundbeck and a number of generic producers.
Big Pharma
AG advises CJEU to uphold €94 million pay-for-delay fine
5 June 2020   The advocate general has recommended that the Court of Justice of the European Union uphold an almost €94 million fine imposed on Lundbeck for its pay-for-delay scheme.

More features

President Trump 2.0: Five major areas to watch
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court